leadf
logo-loader
view4D pharma PLC

4D Pharma’s Blautix “safe and well-tolerated”

The pharmaceutical firm has successfully completed phase I clinical trials for its IBS treatment Blautix

A scientist testing some samples in a lab
Phase I trials typically only assess the safety of a new drug and not its effectiveness

Biotherapeutics firm 4D Pharma PLC (LON:DDDD) Irritable Bowel Syndrome (IBS) treatment, Blautix has passed a phase I clinical trial.

“We have shown Blautix to be safe and well tolerated,” said chief executive Duncan Peyton.

“This trial is providing patient samples that will give the company a better understanding of what is happening in IBS patients undergoing the treatment of Blautix.”

4D is now analysing the samples and data from the trials in greater detail to help develop its understanding of Blautix and to help design the next round of trials.

Phase I trials assess the safety of the drug. The next stage, phase II, is the first test of a new treatment’s efficacy.

Shares rose 19.5p or 2.4% to 850p.

Quick facts: 4D pharma PLC

Price: 95.6 GBX

LSE:DDDD
Market: LSE
Market Cap: £125.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4D Pharma shares could re-test 2016’s £10 highs if they do this one thing

The 4D Pharma (LON:DDDD) share price could go on to re-test last year’s highs of £10 if they can break above the 200-day moving average, claims Zak Mir. “Really, one would want to see the shares break outside that range in order to determine fresh direction,” Mir explains in the Proactive...

on 13/1/17

2 min read